Andrew Greenstein

Andrew Greenstein is a pragmatic scientist with extensive experience in small molecule and antibody discovery, spanning from initial research to phase III clinical support.

Skilled at fostering productive relationships across various sectors including Gilead functional areas, CROs, consultants, key opinion leaders, and academic collaborators.

Proficient in establishing scientific vision, aligning objectives internally and externally, preserving accountability, managing project timelines, coordinating cross-functional teams, and facilitating strategic decision-making.

Currently leads a research team focusing on the development of the first-in-class immuno-oncology drug candidate, Andecaliximab (anti-MMP9).

His educational background includes a PhD in Biochemistry and Molecular Biology from the University of California, Berkeley, and a B.S. in Biochemistry from the University of Connecticut.

Andrew has held key positions such as Director of Translational Science at Corcept Therapeutics, Associate Director of Translational Science at Corcept Therapeutics, and various research scientist roles at Gilead Sciences.

He has also been affiliated with prestigious institutions like the National Science Foundation, UC Berkeley, Pfizer, and the Howard Hughes Medical Institute.